Stopping long-term nucleos(t)ide analogue therapy increases hepatitis B virus (HBV) surface antigen (HBsAg) loss rates in HBV e antigen (HBeAg)-negative patients. Viral rebound may induce immune responses facilitating functional cure. We analyzed which factors are associated with timing of virological relapse in 220 Asian HBeAg-negative patients from the prospective ABX203 vaccine study. Unexpectedly, only the type of antiviral therapy was significantly associated with early virological relapse, defined as an HBV DNA load of >2000 IU/mL until week 12, and relapse occurred earlier in patients treated with tenofovir versus those treated with entecavir (median time, 6 vs 24 weeks; P < .0001). This should be considered for future trials and monitoring of patients after treatment discontinuation.
Treatment with the nucleos(t)ide analogues (NAs) tenofovir or entecavir is the current mainstay of therapy for chronic hepatitis B (CHB). Whereas NA therapy can be discontinued in some hepatitis B virus e antigen (HBeAg)-positive patients after seroconversion, current guidelines usually recommend treatment until HBV surface antigen (HBsAg) seroclearance in HBeAg-negative patients [1, 2] . The concept of earlier treatment discontinuation in HBeAg-negative patients with CHB first appeared in the Asian Pacific Association for the Study of the Liver guidelines and has also been suggested in other current international guidelines [1, 2] . Although one third of patients remain in virological remission, relapse is common in the first months after treatment discontinuation [3] . Several studies have shown that treatment discontinuation during HBeAg-negative CHB can foster a decline in the HBsAg level and, in some patients, even HBsAg loss, presumably by inducing immune responses [4] [5] [6] [7] . We showed that the peak rebound in the HBV DNA level at week 12 after stopping treatment was associated with a subsequent decline in the HBsAg level [5] . However, the optimal time to reinitiate antiviral therapy in patients with viral relapse is not well defined. Thus, early virological relapse may be of particular importance for inducing an immune response against HBV, which could have beneficial long-term effects. To assess factors associated with the timing of virological relapse, we used data derived from the largest prospective trial to have analyzed relapse after stopping NA therapies.
METHODS
Data from the present study were derived from the ABX203 study. The ABX203 study is a randomized, multicenter study investigating whether ABX203 (Nasvac; Center for Genetic Engineering and Biotechnology, Cuba) influences the risk for virological relapse in HBeAg-negative patients after cessation of NA therapy (clinical trials registration NCT02249988). All patients gave informed consent to participate in the study.
Patients were enrolled from 38 centers in 7 countries in the Asia-Pacific region. Inclusion criteria were age of 18-65 years and receipt of NA treatment for at least 2 years. Included patients were HBeAg negative and anti-HBe antibody positive for at least 1 year before screening. Of note, the majority of patients (85.9%) were HBeAg negative before introduction of NA therapy. HBV DNA levels were <40 IU/mL, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were less than or equal to the upper limit of normal for at least 1 year before and at the time of screening.
Exclusion criteria were a platelet count of <100 000/mm 3 or a platelet count of <150 000/mm 3 with esophageal varices and a spleen size of >12 cm, a liver stiffness of 11 kPa (as measured by elastography, using FibroScan) or an AST to platelet ratio index of >2, hepatocellular carcinoma, decompensation, coinfection, concomitant liver disease, immunosuppressive disorder/treatment, and/or treatment with pegylated interferon in the last 12 months before screening.
After 24 weeks, NA therapy was stopped in all patients. Follow-up was until 24 weeks or NA retreatment. Patients were followed up every 2 weeks during the first 8 weeks and then every 4 weeks thereafter. The primary end point of the study was virological remission (defined as an HBV DNA level of <40 IU/mL) through week 24 after stopping NA therapy. Importantly, in the same study ABX203 did not influence the risk of virological relapse when administered simultaneously with NA therapy [8] .
All 224 patients treated with entecavir or tenofovir were selected for analysis (Supplementary Figure 1) . Four patients were subsequently excluded because of missing follow-up data.
Laboratory tests in this study were performed using standard procedures. Virological relapse was defined as a HBV DNA level of >2000 IU/mL. In addition, a more restrictive threshold of HBV DNA >200 IU/mL for virological relapse was also evaluated. The test was not repeated if virological relapse was detected. The Cobas AmpliPrep/Cobas TaqMan HBV Test, version 2.0, with a lower limit of <20 IU/mL, was used for HBV DNA quantification. Graph Pad Prism 6.0 (GraphPad Software, La Jolla, CA) and SPSS 24.0 (IBM, Ehningen, Germany) were used for statistical analysis. All data are presented either as absolute numbers or as mean values (ranges) unless otherwise stated. Continuous data were analyzed with Mann-Whitney U test, and categorical data were analyzed with the Fisher exact test. The log-rank test was used for Kaplan-Meier survival analysis. Multiple logistic regression was used to identify parameters associated with virological relapse between baseline and week 12 and between weeks 16 and 24.
RESULTS
In total, 220 patients primarily from Asia who were treated with entecavir (n = 154) or tenofovir disoproxil fumarate (n = 66) were included in the present study (Table 1) .
Overall, virological relapse (ie, an HBV DNA level of >2000 IU/mL) was documented in 54 patients (24.5%) until week 12 and in 126 (57.3%) until week 24. Thus, late relapse between weeks 16 and 24 occurred in 72 patients (32.7%). Among the patients treated with tenofovir, 71% (47 of 66) had virological relapse until week 12, whereas 4.5% of patients (7 of 154) treated with entecavir had virological relapse in the same period (P < .0001). Type of antiviral therapy, sex, and age were significantly different between patients with early relapse and those with late relapse (Table 1) . To assess factors associated with early versus late relapse, we performed multiple logistic regression for antiviral therapy, sex, age, ALT level, HBeAg status prior to NA therapy, and HBsAg level during early (week 0-12) versus late (week 16-24) virological relapse, defined as an HBV DNA level of >2000 IU/ml. No significant differences were detected for ALT level, sex, age, HBeAg status, and HBsAg level, whereas only the type of antiviral (entecavir vs tenofovir) was significantly associated with the timing of virological relapse (P < .001; Table 1 ).
The median time to virological relapse (ie, an HBV DNA level of >2000 IU/mL) was 6 weeks after tenofovir treatment discontinuation and 24 weeks after entecavir treatment discontinuation (P < .0001; Figure 1 ). This was similar if virological relapse was defined more restrictively (HBV DNA level of >200 IU/mL) (Supplementary Figure 2 ). An additional analysis of 189 patients who were negative for HBeAg before NA initiation showed a similar result (Supplementary Figure 3) .
DISCUSSION
Our results show that the type of NA treatment affects the timing of HBV relapse after cessation of therapy. We here validate recent findings by Su et al that virological relapse after the cessation of entecavir therapy occurs much later than after the cessation of tenofovir therapy [9] .
This has important implications. Until now, no major difference between entecavir and tenofovir in terms of antiviral efficacy or patient outcomes have been reported for treatment-naive patients, and the choice of treatment has been up to the physician and mainly based on lamivudine resistance, costs, or certain comorbidities (ie, renal insufficiency) [1, 2, 10] . Given the present findings, there may be more factors to consider when choosing an NA. First, patients treated with entecavir will require close follow-up for even >3 months after treatment discontinuation. Second, and maybe even more importantly, the timing of HBV DNA relapse after treatment cessation might influence the impact of cessation on the decline in HBsAg levels, owing to factors such as differences in the duration of immune responses after stopping therapy. Similar findings were observed in our recently published small pilot trial in mainly European patients with a follow-up of 48 weeks [5] . All patients who stopped entecavir therapy experienced a late HBV DNA relapse after 12 weeks, and all patients who stopped tenofovir therapy experienced a relapse by week 8 (Supplementary Figure 4; data not shown previously [5] ). Interestingly, only patients with an early relapse had a >1-log decrease in the HBsAg level at week 48 in our previous study [5] . The reason for the difference between entecavir and tenofovir is unknown but might include differences in pharmacokinetics or interaction with immune responses. Although the half-life of the active compound of tenofovir and entecavir is similar, terminal elimination of entecavir may take up to 149 hours [11] , but this hardly explains the difference of several weeks in the onset of virological relapse we observed here. A recent study found that tenofovir but not entecavir leads to an induction of interferon λ [12] . Indeed, it is not clear whether tenofovir or entecavir is special as compared to all other NAs. A retrospective study has shown that the time to relapse after stopping lamivudine or telbivudine therapy was also faster than the time to relapse after entecavir treatment [13] . Future studies are warranted to unveil the mechanistic process involved in entecavir-associated prolonged HBV DNA suppression.
Our study has some limitations. Given the follow-up duration of 24 weeks, it is likely that some patients treated with entecavir will experience virological relapse at a later point in time, but relapse at a later point in time would not change our conclusion. However, bias cannot fully be excluded because some contributing factors, such an NA treatment duration of >2 years or the presence of NA resistance, were not assessed and because virological relapse was not confirmed immediately by a repeated test. In Asia, entecavir was approved earlier than tenofovir, but this was not an issue for our European cohort, which showed similar results [5] . However, the duration of consolidation therapy may influence the timing of relapse. Owing to the short follow-up period (ie, until relapse or week 24 after NA treatment cessation), we could not investigate whether the timing of relapse affects HBsAg level decline or HBsAg loss rates. In addition, the study was not designed to address different dynamics of virological relapse between tenofovir and entecavir. Nevertheless, the study was prospective, and the primary end point was virological remission, paralleling a study design that would be suitable to assess differences between tenofovir and entecavir. Our study and the study by Su et al were conducted in Asian patients. Whether our findings in this population will also be true for non-Asian patients remain to be confirmed, although our small study showed similar patterns in mainly Caucasian or European patients [5] . In comparison to the study by Su et al, our study included more than twice as many patients, and >85% of patients were HBeAg negative before introduction of NA therapy. In summary, this is the largest prospective study to show that the type of NA treatment affects the timing of relapse after cessation of therapy. This is an important finding for clinical practice, as well as for future studies addressing whether treatment discontinuation has an impact on functional cure of HBV infection.
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